参考文献/References:
[1]Papadimitriou L,Hamo CE,Butler J.Heart failure guidelines:what′s new[J].Trends Cadiovasc Med,2017,27(5):316-323.
[2]Mahmood SS,Wang TJ.The epidemiology of congestive heart failure:the Framingham Heart Study perspective[J].Glob Heart,2013,18(1):77-82.
[3]Duschek N,Skrinjar E,Waldhr T,et al.N-terminal pro B-type natriuretic peptide is a predictor of long-term survival in malepatients of 75 years and older with high-grade asymptomatic internal carotidartery stenosis[J].Vase Surg,2011,53(5):1242-1250.
[4]Eugene Braunwald.The war against heart failure:the Lancet lecture[J].Lancet,2015,385(9970):812-824.
[5]Kociol RD,Fonarow GC,Klaskala W,et al.Generalizability and longitudinal outcomes of a national heart failure clinical registry:Comparison of Acute Decompensated Heart Failure National Registry and non-ADHERE Medicare beneficiaries[J].Am Heart,2010(160):885-892.
[6]Giamouzis G,Kalogeropoulos A,Georgiopoulou V’Laskar S,et al.Hospitalization epidemic in patients with heart failure:risk factors,risk prediction,knowledge gaps,and future directions[J].J Card Fail,2011(17):54-75.
[7]Foks AC,Lichtman AH,Kuiper J.Treating atherosclerosis with regulatory T cells[J].Arterioscler Thromb Vase Biol,2015,35(2):280-287.
[8]Yancy MD,MSc,FACC,et al.Immediate Past Chair,et al.2013 ACCF/AHA Guideline for the Management of Heart Failure[J].Journal of the American College of Cardiology,2013,62(16):147-239.
[9]van Veldhuisen DJ,Linssen C,Jaarsmat T,et al.B-type natriuretic peptide and prognosis in heart failure patients with p-reserved and reduced ejection fraction[J].J Am Coil Cardiol,2013,61(14):1498-1506.
[10]Uthamalingams,Kandala J,Daley M,et al.serum albumin and mortality in acutely decompensated heart failure[J].Am Heart J,2010,160(6):1149-1155.
[11]Kinugasa Y,Kato M,Sugihara S,et al.A simple risk score to predict in hospital death of elderly patients with acute decompensated heart failure-hypoalbuminemia as an additional prognostic factor[J].Circ J,2009,73(12):2276-2281.
[12]Horwich TB,Hernandez AF,Dai D,et al.Cholesterol levels and in-hospital mortality in patients with acute decompensated heart failure[J].American Heart Journal,2008,156(6):1170-1176.
[13]孙奡燕,刘永,赵雅琳,等.不同时点血浆脑钠肽及超敏C-反应蛋白水平与老年非ST段抬高急性心肌梗死患者预后关系[J].中国急救医学,2016,36(9):804-807.
[14]中华医学会心血管病学分会心力衰竭学组,中国医师协会心力衰竭专业委员会.中华心血管病杂志编辑委员会.中国心力衰竭诊断和治疗指南2018[J].中华心血管病杂志,2018,46(10):760-789.
[15]Kourie JI,Rive MJ.Role of natriuretic peptides in ion transport mechanisms[J].Medicinal Research Reviews,2015,19(1):75-94.
[16]Karahan SC,Koramaz I,Ahun G,et al.Ischemiamodified albumin reduction after coronary bypass surgery is associated with thecardioprotective efficacy of cold-blood cardioplegia enriched with N-aeetylcysteine:a preliminary study[J].Eur Surg Res,2015,44(1):30-36.
[17]Abhashi SA,Kryeziu FU,Nazreku FD.Increased carotid intima-media thickness associated with high hs-CRP levels is a predictor of unstable coronary artery disease[J].Cardiovasc J A fr,2013,24 (7):270-273.
[18]Sargento L,Satendra M,Almeiidal I,et al.Nutritional status of geriatric outpatients with lisystolic heart failure and its prognostic value regarding death or hospitalization,biomarkers and quality of life[J].J Nutr Health Aging,2013(17):300-304.
[19]Von HS,Stepney R,Anker SD.Advances in understanding and treating cardiac cachexia: highlights from the 5th Cachexia Conference[J].International Journal of Cardiology,2010,144(3):347-349.
[20]Kung T,Szabó T,Springer J,et al.Cachexia in heart disease: highlights from the ESC 2010[J]. Journal of Cachexia Sarcopenia&Muscle,2011,2(1):63-69.
相似文献/References:
[1]郭俊林,张立.BNP对CRT后期疗效的临床评价[J].医学信息,2018,31(01):67.[doi:10.3969/j.issn.1006-1959.2018.01.024]
GUO Jun-lin,ZHANG li.Clinical Evaluation of BNP in Treatment of Late CRT[J].Medical Information,2018,31(05):67.[doi:10.3969/j.issn.1006-1959.2018.01.024]
[2]程 林.重组人脑利钠肽用于重症急性心肌炎伴
心力衰竭患者治疗的临床研究[J].医学信息,2018,31(08):126.[doi:10.3969/j.issn.1006-1959.2018.08.042]
CHENG Lin.Clinical Study of Recombinant Human Brain Natriuretic Peptide in the Treatment of Patients with Severe Acute Myocarditis and Heart Failure[J].Medical Information,2018,31(05):126.[doi:10.3969/j.issn.1006-1959.2018.08.042]
[3]胡丽君.螺内酯联合曲美他嗪治疗慢性心力衰竭的疗效分析[J].医学信息,2018,31(08):131.[doi:10.3969/j.issn.1006-1959.2018.08.044]
HU Li-jun.Efficacy of Spironolactone Combined with Trimetazidine in the Treatment of Chronic Heart Failure[J].Medical Information,2018,31(05):131.[doi:10.3969/j.issn.1006-1959.2018.08.044]
[4]李 铎,王建华.盐酸曲美他嗪片辅助治疗对冠心病伴心力衰竭患者氧化应激、心肌功能的影响[J].医学信息,2018,31(10):126.[doi:10.3969/j.issn.1006-1959.2018.10.041]
LI Duo,WANG Jian-hua.Effect of Trimetazidine Hydrochloride Tablets Adjuvant Therapy on Oxidative Stress and Myocardial Function in Patients with Coronary Heart Disease Complicated with Heart Failure[J].Medical Information,2018,31(05):126.[doi:10.3969/j.issn.1006-1959.2018.10.041]
[5]平兰芝,黄小楼,胡天俊,等.CaMKⅡ在心血管疾病中的研究[J].医学信息,2022,35(10):59.[doi:10.3969/j.issn.1006-1959.2022.10.014]
PING Lan-zhi,HUANG Xiao-lou,HU Tian-jun,et al.Research on the Role of CaMKⅡ in Cardiovascular Diseases[J].Medical Information,2022,35(05):59.[doi:10.3969/j.issn.1006-1959.2022.10.014]
[6]刘革铭,马洪俊,刘 毅,等.心力衰竭的机制及诊疗的研究[J].医学信息,2022,35(10):91.[doi:10.3969/j.issn.1006-1959.2022.10.022]
LIU Ge-ming,MA Hong-jun,LIU Yi,et al.Mechanism, Diagnosis and Treatment of Heart Failure[J].Medical Information,2022,35(05):91.[doi:10.3969/j.issn.1006-1959.2022.10.022]
[7]黄光明,赵兴昌,符显昭.水中运动联合中药内治对糖尿病大鼠心肌细胞凋亡和心功能的影响[J].医学信息,2022,35(11):72.[doi:10.3969/j.issn.1006-1959.2022.11.020]
HUANG Guang-ming,ZHAO Xing-chang,FU Xian-zhao.Effects of Aquatic Therapeutic Exercise Combined with Traditional Chinese Medicine Internal Treatment on Cardiomyocyte Apoptosis and Cardiac Function in Diabetic Rats[J].Medical Information,2022,35(05):72.[doi:10.3969/j.issn.1006-1959.2022.11.020]
[8]何玲玲,程淑芬.曲美他嗪联合琥珀酸美托洛尔治疗冠心病心力衰竭疗效观察[J].医学信息,2018,31(13):142.[doi:10.3969/j.issn.1006-1959.2018.13.042]
HE Ling-ling,CHENG Shu-fen.Therapeutic Effect of Trimetazidine Combined with Metoprolol Succinate in the Treatment of Coronary Heart Disease with Heart Failure[J].Medical Information,2018,31(05):142.[doi:10.3969/j.issn.1006-1959.2018.13.042]
[9]赵 维,廖荣宏,王爱华.糖皮质激素治疗心力衰竭疗效与安全性的Meta分析[J].医学信息,2018,31(14):70.[doi:10.3969/j.issn.1006-1959.2018.14.021]
ZHAO Wei,LIAO Rong-hong,WANG Ai-hua.Meta-analysis of the Efficacy and Safety of Glucocorticoids in the Treatment of Heart Failure[J].Medical Information,2018,31(05):70.[doi:10.3969/j.issn.1006-1959.2018.14.021]
[10]施国富,吴春阳,施亚明,等.血浆脑钠肽对射血分数保留心力衰竭患者的诊断价值研究[J].医学信息,2018,31(16):47.[doi:10.3969/j.issn.1006-1959.2018.16.013]
SHI Guo-fu,WU Chun-yang,SHI Ya-ming,et al.Diagnostic Value of Plasma Brain Natriuretic Peptide in Patients with Heart Failure Preserved by Ejection Fraction[J].Medical Information,2018,31(05):47.[doi:10.3969/j.issn.1006-1959.2018.16.013]